GlassScriptPhysician profile
Misty Ralyea
NPI 1386949873
$4,234.13
in general payments reported to CMS, 2019-2025
32 companies · $901 in 2025
The $901 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,264 · 2022: $1,098 · 2023: $382 · 2024: $590 · 2025: $901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,871.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $831.98 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $583.10 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $391.10 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $353.18 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $176.68 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Dexcom, INC. | $171.72 | 2023-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $164.13 | 2021-2022 | |
| Glaxosmithkline, LLC. | $149.36 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $140.26 | 2021-2022 | |
| Ardelyx, INC. | $112.21 | 2022-2024 | Ibsrela |
| Qol Medical, LLC | $107.75 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $98.02 | 2021-2022 | |
| Exact Sciences Corporation | $95.55 | 2023-2025 | Cologuard Collection Kit |
| Janssen Biotech, INC. | $92.80 | 2021-2022 | |
| Redhill Biopharma INC. | $88.22 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $83.17 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $78.44 | 2024-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $67.68 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $53.54 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $45.17 | 2021-2022 | |
| Amgen INC. | $44.23 | 2023-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $42.43 | 2021-2022 | |
| Axsome Therapeutics, INC. | $37.92 | 2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.16 | 2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.53 | 2025 | Caplyta |
| Evoke Pharma, INC. | $28.47 | 2021-2022 | |
| Celgene Corporation | $27.16 | 2021 | |
| Genzyme Corporation | $24.98 | 2022 | |
| Shield Therapeutics INC | $23.06 | 2023 | Accrufer |
| Abbott Laboratories | $21.02 | 2023 | Freestyle Libre 2 |
| Esperion Therapeutics, INC. | $19.80 | 2025 | Nexletol |
| Intra-Sana Laboratories | $15.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Misty Ralyea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.